<code id='C0A3DB8D43'></code><style id='C0A3DB8D43'></style>
    • <acronym id='C0A3DB8D43'></acronym>
      <center id='C0A3DB8D43'><center id='C0A3DB8D43'><tfoot id='C0A3DB8D43'></tfoot></center><abbr id='C0A3DB8D43'><dir id='C0A3DB8D43'><tfoot id='C0A3DB8D43'></tfoot><noframes id='C0A3DB8D43'>

    • <optgroup id='C0A3DB8D43'><strike id='C0A3DB8D43'><sup id='C0A3DB8D43'></sup></strike><code id='C0A3DB8D43'></code></optgroup>
        1. <b id='C0A3DB8D43'><label id='C0A3DB8D43'><select id='C0A3DB8D43'><dt id='C0A3DB8D43'><span id='C0A3DB8D43'></span></dt></select></label></b><u id='C0A3DB8D43'></u>
          <i id='C0A3DB8D43'><strike id='C0A3DB8D43'><tt id='C0A3DB8D43'><pre id='C0A3DB8D43'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:explore    Page View:43119
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In